1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4):378-390. doi:10.1056/NEJMoa0708857
2. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. The Lancet Oncology 10 (1):25-34. doi:10.1016/s1470-2045(08)70285-7
3. Cheng A-L, Kang Y-K, Lin D-Y, Park J-W, Kudo M, Qin S, Chung H-C, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E (2013) Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical Oncology 31 (32):40674075. doi:10.1200/jco.2012.45.8372
4. Johnson PJ, Qin S, Park J-W, Poon RTP, Raoul J-L, Philip PA, Hsu C-H, Hu T-H, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han K-H, Paik S-W, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak W-Y, Jeng L-B, Liu D, Ezzeddine R, Walters I, Cheng A-L (2013) Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology 31 (28):3517-3524. doi:10.1200/jco.2012.48.4410
5. Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, Kudo M, Kang Y-K, Chen P-J, Toh H-C, Gorbunova V, Eskens FALM, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S (2015) Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology 33 (2):172-179. doi:10.1200/jco.2013.54.3298
6. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31 (28):3509-3516. doi:10.1200/jco.2012.47.3009
7. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. Jama 312 (1):57-67. doi:10.1001/jama.2014.7189
8. Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T (2017) S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol 2 (6):407-417. doi:10.1016/s24681253(17)30072-9
9. Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19 (5):682-693. doi:10.1016/s1470-2045(18)30146-3
10. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129 (1):245-255. doi:10.1002/ijc.25864
11. Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, Lederle W (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12 (7):1322-1331. doi:10.1158/1535-7163.Mct-12-1162
12. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (10064):5666. doi:10.1016/s0140-6736(16)32453-9
13. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, Baron A, Park J-W, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng A-L (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 391 (10126):1163-1173. doi:10.1016/s0140-6736(18)30207-1
14. Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H (2020) REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55 (1):113-122. doi:10.1007/s00535-019-01642-1
15. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, McDonald GB, Nichols WG, Radich J, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C (2003) Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (3):820-826. doi:10.1182/blood-2002-11-3567
16. Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, Astier A, Chatelut E (2014) Review of therapeutic drug monitoring of anticancer drugs part 1-cytotoxics. Eur J Cancer 50 (12):2010-2019. doi:10.1016/j.ejca.2014.04.014
17. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (8):3496-3499. doi:10.1182/blood-2006-07-036012
18. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A (2014) Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. Eur J Cancer 50 (12):2020-2036. doi:10.1016/j.ejca.2014.04.015
19. Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H (2016) Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol 78 (2):377-382. doi:10.1007/s00280-016-3097-4
20. Nagahama M, Ozeki T, Suzuki A, Sugino K, Niioka T, Ito K, Miura M (2019) Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol 36 (5):39. doi:10.1007/s12032-019-1263-3
21. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52 (4):512-519. doi:10.1007/s00535-016-1263-4
22. Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H (2017) Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. J Clin Pharmacol 57 (9):1138-1147. doi:10.1002/jcph.917
23. Dubbelman AC, Rosing H, Thijssen B, Gebretensae A, Lucas L, Chen H, Shumaker R, Schellens JH, Beijnen JH (2012) Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 887-888:25-34. doi:10.1016/j.jchromb.2012.01.004
24. Mano Y, Kusano K (2015) A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis. J Pharm Biomed Anal 114:82-87. doi:10.1016/j.jpba.2015.05.008
25. Ogawa-Morita T, Sano Y, Okano T, Fujii H, Tahara M, Yamaguchi M, Minami H (2017) Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. Int J Anal Chem 2017:2341876. doi:10.1155/2017/2341876
26. Mano Y (2018) Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS. Pract Lab Med 12:e00103. doi:10.1016/j.plabm.2018.e00103
27. Watanabe Y, Doki K, Sekine I, Hara H, Homma M (2020) High-Performance Liquid Chromatography for Therapeutic Drug Monitoring of Serum Lenvatinib. Ther Drug Monit 42 (4):554-558. doi:10.1097/ftd.0000000000000770
28. Food and Drug Administration (2001), Center for drug evaluation and research, Guidance for Industry BioanalyticalMethod validation. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-ValidationGuidance-for-Industry.pdf. Accessed 24 November 2020
29. European medicines agency (2011), Guideline on bioanalytical method validation.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guid eline/2011/08/WC500109686.pdf. Accessed 24 November 2020
30. 厚生労働省医薬食品局審査管理課長通知(2013), 医薬品開発における生体試 料中薬物濃度分析法のバリデーションに関するガイドライン http://www.nihs.go.jp/drug/BMV/250711_BMV-GL.pdf. Accessed 24 November 2020
31. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008) Multikinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14 (17):54595465. doi:10.1158/1078-0432.Ccr-07-5270
32. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122 (3):664-671. doi:10.1002/ijc.23131
33. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. doi:10.1155/2014/638747
34. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372 (7):621-630. doi:10.1056/NEJMoa1406470
35. Wilson LJ, Linley A, Hammond DE, Hood FE, Coulson JM, MacEwan DJ, Ross SJ, Slupsky JR, Smith PD, Eyers PA, Prior IA (2018) New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Cancer Res 78 (1):15-29. doi:10.1158/0008-5472.Can-17-2291
36. Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T (2014) Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer 14:530. doi:10.1186/1471-2407-14-530
37. Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z (2016) Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 81 (6):1124-1133. doi:10.1111/bcp.12907
38. Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N (2014) Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer 110 (10):2441-2449. doi:10.1038/bjc.2014.194
39. Gunther M, Saxinger L, Gray M, Legatt D (2013) Two suspected cases of immunoglobulin-mediated interference causing falsely low vancomycin concentrations with the Beckman PETINIA method. Ann Pharmacother 47 (4):e19. doi:10.1345/aph.1R566
40. レンビマ®カプセル 4mg[添付文書]. エーザイ株式会社
41. Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS (2019) The Role of Angiogenesis in Hepatocellular Carcinoma. Clinical Cancer Research 25 (3):912-920. doi:10.1158/1078-0432.ccr-18-1254
42. Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical Pharmacology & Therapeutics 102 (5):765-776. doi:10.1002/cpt.787
43. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer 111 (10):1909-1916. doi:10.1038/bjc.2014.503
44. Yu H, Steeghs N, Kloth JSL, De Wit D, Van Hasselt JGC, Van Erp NP, Beijnen JH, Schellens JHM, Mathijssen RHJ, Huitema ADR (2015) Integrated semiphysiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology 79 (5):809-819. doi:10.1111/bcp.12550
45. Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ (2013) Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. The Journal of Clinical Pharmacology 53 (5):491-504. doi:10.1002/jcph.73
46. Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T (2015) Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer 13 (4):350-358. doi:10.1016/j.clgc.2015.01.007
47. Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T (2018) Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Med Oncol 35 (4):51. doi:10.1007/s12032-0181113-8
48. Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2015) Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol 10 (3):429-437. doi:10.1007/s11523-014-0349-2
49. Pharmaceuticals and Medical Devices Agency (2018) Lenvima Review Reports. https://www.pmda.go.jp/files/000233542.pdf. Accessed 19 June 2020
50. Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, Saiag P (2015) Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Ann Oncol 26 (7):1470-1475. doi:10.1093/annonc/mdv189
51. Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, Miura M (2019) Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Scientific Reports 9(1):5404. DOI: 10.1038/s41598-019-41820-y
52. Food and Drug Administration (2014) Center for Drug Evaluation and Research Lenvatinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000ClinPh armR.pdf. Accessed 19 June 2020
53. Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for Hcc Study Group HCCG (2019) Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 8 (8):3719- 3728. doi:10.1002/cam4.2241
54. Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K (2019) Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel) 11 (11). doi:10.3390/cancers11111769
55. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M (2017) Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer 6 (4):325-336. doi:10.1159/000479984
56. Fuchigami A, Imai Y, Uchida Y, Uchiya H, Fujii Y, Nakazawa M, Ando S, Sugawara K, Nakayama N, Tomiya T, Mochida S (2020) Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLoS One 15 (4):e0231427. doi:10.1371/journal.pone.0231427
57. Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J (2015) A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol 93 (3):203-210. doi:10.1016/j.critrevonc.2014.10.006
58. Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N (2019) Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and PostRegorafenib Therapies in Real World Practice. Cancers (Basel) 11 (10). doi:10.3390/cancers11101517
59. Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H (2019) Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel) 12 (1). doi:10.3390/cancers12010049
60. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66 (2):357-371. doi:10.1007/s00280-009-1170-y
61. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27 (19):3141-3147. doi:10.1200/jco.2008.20.4818
論文の公開元へ
